Status of Vitamin D-25 Hydroxy Vitamin D-25 (OH) in Patients With Multiple Myeloma

Donaryn V. Pasamonte¹, Flordeluna Z. Mesina M.D.²

ABSTRACT

Introduction  Multiple myeloma (MM) causes generalized bone loss leading to lytic bone lesions and pathologic fractures. The increased osteoclast activity and reduced osteoblast function favors bone resorption and decreased bone formation. Vitamin D is vital in regulating calcium homeostasis and osteoclast-mediated bone resorption. Deficiency of Vitamin D among MM patients may complicate bone mineralization problems and fractures.

Objective

General Objective To determine the status of Vitamin D in patients with multiple myeloma

Specific Objective To determine the levels of Vitamin D, intact parathyroid hormone and ionized calcium among MM patients

Methodology This is a prospective, cross-sectional study which included patients who were 18 years old and above, male or female, diagnosed with MM at the University of Santo Tomas Hospital, with or without treatment. Excluded in the study were those with Vitamin D and calcium supplementation. Eligible subjects were extracted blood for Vitamin D assay, intact parathyroid hormone and ionized calcium.

Results A total of 22 patients with MM were included in the study. Sixteen patients (72.7%) had hypovitaminosis D. Among these sixteen patients, seven (31.8%) had Vitamin D deficiency (Vitamin D levels <20 ng/mL [50 nmol/L]) and nine (40.9%) had Vitamin D insufficiency (levels of 21-29 ng/mL [52.5-72.5 nmol/L]). Only 6 (27.3%) of them were found to have normal serum Vitamin D (levels of >29 ng/mL >72.5 nmol/L). The mean age (p=0.069), intact PTH (p=0.062) and ionized calcium (p=0.188) of the three groups of patients did not differ.

Conclusion This study found a high incidence of Vitamin D deficiency among MM patients seen at the University of Santo Tomas Hospital. Vitamin D deficiency was independent of age, intact PTH and ionized calcium. It was more common in male subjects. Patients with hypovitaminosis D are at risk of having secondary hyperparathyroidism.

Recommendation Vitamin D status should be determined among patients with MM. Early recognition and treatment of hypovitaminosis D will prevent the risk of having secondary hyperparathyroidism that can complicate skeletal-related events.

INTRODUCTION

Multiple myeloma (MM) is an abnormal proliferation of plasma cells in the bone marrow. The clinical manifestation is variable, which can range from...
being asymptomatic to multi-organ involvement. This plasma cell malignancy affects mostly the kidneys and the skeletal system causing renal insufficiency, hypercalcemia, hyperviscosity and bone disease. Skeletal pathology in MM is characterized by generalized bone loss which can present as bone pain, lytic bone lesions or pathologic fractures. These result from increased osteoclast activity and reduced osteoblast function [1,2,3] causing increased bone resorption and decreased bone formation.

Bone health, in general, is maintained by the balance of the following elements: calcium, Vitamin D and parathyroid hormone. Vitamin D is the most important regulator of calcium homeostasis and osteoclast-mediated bone resorption. Hypovitaminosis D adversely affects calcium metabolism, osteoblastic activity, matrix ossification, bone remodeling and bone density [4]. Other consequences of Vitamin D deficiency are secondary hyperparathyroidism and bone loss leading to osteoporosis and fractures, mineralization defects, and muscle weakness causing falls and subsequently leading to more fractures [5]. Incidence of Vitamin D deficiency and insufficiency among MM patients is high [6]. This deficiency can cause generalized musculoskeletal pain and increase risks of fall [7], and hence may create further debilitating problems in this group of patients. In the Philippines, there is no data on the incidence or prevalence of Vitamin D deficiency among MM patients. This study was conducted to determine the status of Vitamin D among this subset of patients from University of Santo Tomas Hospital (USTH).

**MATERIALS AND METHODS**

This is a prospective, cross-sectional study which included patients who were 18 years old and above, male or female, diagnosed with MM at the USTH, with or without treatment. Excluded in the study were those with Vitamin D and calcium supplementation. Written consent was signed by all subjects after thoroughly explaining the study to them. After signing a USTH-Institutional Review Board approved informed consent, subjects were instructed to fast for 8-10 hours prior to blood extraction. The following blood tests were requested: Vitamin D assay, intact parathyroid hormone and ionized calcium. The laboratory tests were done at the USTH laboratory. Specimen acquisition and handling were in accordance with the strict laboratory practice of the USTH clinical pathology laboratory. Results were given to the patient, attending physician and investigator for data collection, recording and analysis.

**STATISTICAL ANALYSES**

MM patients’ mean and range of vitamin D are presented in Table 1. Means and standard deviations summarized the data in quantitative form, such as age, intact parathyroid hormone (PTH), ionized calcium, albumin, globulin and total protein (TP). Counts

### Table 1. Demographic and serum profile of multiple myeloma patients

<table>
<thead>
<tr>
<th>Vitamin D level</th>
<th>ALL</th>
<th>Normal</th>
<th>Insufficient</th>
<th>Deficient</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>22</td>
<td>6</td>
<td>9</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.36 ± 10.06</td>
<td>64.17 ± 5.74</td>
<td>61.44 ± 10.70</td>
<td>58.86 ± 10.93</td>
<td>0.659</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>10/12</td>
<td>2/4</td>
<td>7/2</td>
<td>1/6</td>
<td></td>
</tr>
<tr>
<td>ECOG score: 0</td>
<td>8 (36.4%)</td>
<td>2 (33.3%)</td>
<td>4 (44.4%)</td>
<td>2 (28.6%)</td>
<td>1.000</td>
</tr>
<tr>
<td>1</td>
<td>5 (22.7%)</td>
<td>1 (16.7%)</td>
<td>2 (22.2%)</td>
<td>2 (28.6%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>9 (40.9%)</td>
<td>3 (50%)</td>
<td>3 (33.3%)</td>
<td>3 (42.9%)</td>
<td></td>
</tr>
<tr>
<td>Intact PTH</td>
<td>26.58 ± 14.79</td>
<td>14.86 ± 5.74</td>
<td>32.23 ± 14.01</td>
<td>29.36 ± 16.79</td>
<td>0.062</td>
</tr>
<tr>
<td>Normal/Decreased</td>
<td>16/6</td>
<td>2/4</td>
<td>9/0</td>
<td>5/2</td>
<td>0.011</td>
</tr>
<tr>
<td>Ionized Calcium</td>
<td>1.35 ± 0.29</td>
<td>1.24 ± 0.03</td>
<td>1.48 ± 0.41</td>
<td>1.26 ± 0.17</td>
<td>0.188</td>
</tr>
<tr>
<td>Albumin</td>
<td>3.74 ± 0.62</td>
<td>3.76 ± 0.57</td>
<td>3.41 ± 0.65</td>
<td>4.15 ± 0.38</td>
<td>0.048</td>
</tr>
<tr>
<td>Globulin</td>
<td>3.82 ± 2.06</td>
<td>4.99 ± 2.80</td>
<td>3.74 ± 2.05</td>
<td>2.93 ± 0.87</td>
<td>0.269</td>
</tr>
<tr>
<td>TP</td>
<td>7.65 ± 2.14</td>
<td>8.76 ± 3.00</td>
<td>7.13 ± 1.91</td>
<td>7.23 ± 1.40</td>
<td>0.403</td>
</tr>
</tbody>
</table>

Values expressed as counts (%), or mean ± SD.

M, male; F, female; ECOG, Eastern Cooperative Oncology Group; PTH, parathyroid hormone; TP, total protein
Status of Vitamin D-25 Hydroxy Vitamin D-25 (OH) in Patients With Multiple Myeloma

and percentages summarized the data in qualitative form, such as gender, Eastern Cooperative Oncology Group (ECOG) score, and decreased/normal level of PTH. Single-factor analysis of variance with Tukey’s HSD determined if there were significant differences in the mean age, PTH, ionized calcium, albumin, globulin and TP of patients with normal, insufficient and deficient Vitamin D. Fisher’s exact test determined if there were significant association of levels of Vitamin D with gender, ECOG score and decreased/normal level of PTH. Pearson correlation identified the correlation of PTH, ionized calcium, albumin, globulin and TP. P-values less than 0.05 are considered significant. All statistical tests are performed using R ver 3.2.2.

RESULTS

A total of 22 patients with MM were included in the study. The mean age ($p=0.069$), PTH ($p=0.062$), ionized calcium ($p=0.188$), globulin ($p=0.269$) and TP ($p=0.403$) of the three groups of patients did not differ. Similarly, ECOG scores are not associated with the levels of Vitamin D of patients ($p=1.000$).

Meanwhile, it was evident that gender is associated ($p=0.048$) with the level of Vitamin D, indicating that males are 16.2 times [95% CI: 1.1 to 1008.4] more likely to have vitamin D deficiency as compared to those with insufficient Vitamin D. More male MM patients are suffering from hypovitaminosis D (80%; deficient and insufficient patients combined), compared to their female counterparts (66.7%).

The levels of PTH are significantly associated ($p=0.011$) with their levels of Vitamin D, which implies that patients with insufficient levels of Vitamin D are 97% less likely [OR = 0.03, 95% CI: 0.00 to 0.74] to have decreased PTH compared to those with normal levels of Vitamin D.

Of the 22 patients included in the study, only 6 (27.3%) of them were found to have normal serum Vitamin D, while the remaining 16 (72.7%) had Vitamin D below 29 ng/mL (the normal reference: >29 ng/mL [>72.5 nmol/L]). Seven (31.8%) patients had Vitamin D deficiency (levels <20 ng/mL [50 nmol/L]) and nine (40.9%) were categorized as having insufficient Vitamin D (levels of 21-29 ng/mL [52.5-72.5 nmol/L]).

DISCUSSION

MM remains to be an incurable plasma cell malignancy despite the advent of newer pharmacological treatment modalities [8]. Renal insufficiency and osteolytic bone disorders are among the systemic complications of this disease. Hypercalcemia results from increased bone resorption leading to skeletal-related events like pathologic fractures. The cornerstone in the treatment of high calcium levels among MM patients includes hydration and initiation of bisphosphonates [9].

Vitamin D has a very important role in skeletal physiology as it is required for bone mineralization and formation [10]. The active metabolite 1, 25 (OH) 2D stimulates the absorption of calcium from the intestine [5]. The Vitamin D precursors, D2 and D3 are metabolized to 25-hydroxyvitamin D [25(OH)D] in the liver and serum 25(OH)D is used to assess Vitamin D status [11]. Vitamin D deficiency is defined as a 25(OH)D below 20 ng/mL (50 nmol/L) and Vitamin D insufficiency as a 25(OH)D of 21-29 ng/mL (52.5-72.5 nmol/L) [4].

The major cause of Vitamin D deficiency is lack of sun exposure. It is more prevalent in places with winter season making ultraviolet light (UV) unavailable for the skin to manufacture Vitamin D [11]. In tropical countries like the Philippines, hypovitaminosis D was noted to be common among office workers who stay indoors most of the day. The habitual wearing of long-sleeved clothing and slacks or pants, using too much sunscreen and lack of Vitamin D-rich foods in the diet are all contributory to having Vitamin D deficiency [12].

Studies have proven that there is a high incidence of Vitamin D deficiency among MM patients [6,7]. More importantly, Ng et al. [13] stated that hypovitaminosis D may portend poorer disease outcomes in patients with MM. A study done by Aribi et al. [14] in Algeria concluded that Vitamin D could be
considered as an effective prognostic factor and treatment of MM, especially in patients with monoclonal IgG kappa immunoglobulin. One case study reported a 63-year-old MM patient who had Vitamin D deficiency and highlighted that Vitamin D deficiency can cause generalized musculoskeletal pain and increase risks of fall [8]. Maier et al. [15] also found out that there is widespread and alarming rate of hypovitaminosis D among patients with metastatic bone disease and MM. In that same study, it was concluded that it is important to assess Vitamin D levels among these subsets of patients.

This study confirmed that Vitamin D deficiency is prevalent among MM patients seen at the USTH. Of the 22 patients included in the study, only 6 (27.3%) of them were found to have normal serum Vitamin D, while the remaining 16 (72.7%) had Vitamin D below 29 ng/mL (the normal reference: >29 ng/mL [>72.5 nmol/L]). Seven (31.8%) patients have Vitamin D deficiency (levels <20 ng/mL [50 nmol/L]) and nine (40.9%) were categorized as having insufficient Vitamin D (levels of 21-29 ng/mL [52.5-72.5 nmol/L]). Table 1 details the number of patients belonging to the sufficient, insufficient and deficient groups.

Table 2 compiles the demographics and serum profile of MM patients included in the study. The mean age (p=0.069), PTH (p=0.062), ionized calcium (p=0.188), globulin (p=0.269) and TP (p=0.403) of the three groups of patients did not differ. However, more male MM patients are suffering from hypovitaminosis D (80%; deficient and insufficient patients combined) compared to their female counterparts (66.7%). These Vitamin D-deficient subjects are more likely to have secondary hyperparathyroidism. It is recommended that MM patients should be screened for possible hypovitaminosis D and prompt correction is necessary to avoid further bone loss. The International Myeloma Working Group recommends routine supplementation with calcium and Vitamin D among MM patients receiving bisphosphonate therapy [8]. In a study done by Hospital for Special Surgery in New York, they demonstrated that maintaining a circulating Vitamin D level above 33 ng/mL is associated with more favorable outcome with bisphosphonate therapy among patients with osteoporosis and low mineral density [19]. We recommend that a study be conducted among MM patients to determine if maintaining such a level will also optimize the effects of bisphosphonate in this subset of patients.

**CONCLUSION AND RECOMMENDATIONS**

This study proved that there is a high prevalence of Vitamin D deficiency among MM which matched previous reports by Badros et al. and Laroche et al [17,18]. Our data showed that more male MM patients are suffering from hypovitaminosis D (80%; deficient and insufficient patients combined), compared to their female counterparts (66.7%). These Vitamin D-deficient subjects are more likely to have secondary hyperparathyroidism. It is recommended that MM patients should be screened for possible hypovitaminosis D and prompt correction is necessary to avoid further bone loss. The International Myeloma Working Group recommends routine supplementation with calcium and Vitamin D among MM patients receiving bisphosphonate therapy [8]. In a study done by Hospital for Special Surgery in New York, they demonstrated that maintaining a circulating Vitamin D level above 33 ng/mL is associated with more favorable outcome with bisphosphonate therapy among patients with osteoporosis and low mineral density [19]. We recommend that a study be conducted among MM patients to determine if maintaining such a level will also optimize the effects of bisphosphonate in this subset of patients.

<table>
<thead>
<tr>
<th>Vitamin D level</th>
<th>n</th>
<th>Mean (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>6</td>
<td>42.85 (34.71 – 58.01)</td>
</tr>
<tr>
<td>Insufficient</td>
<td>9</td>
<td>24.08 (20.10 – 28.11)</td>
</tr>
<tr>
<td>Deficient</td>
<td>7</td>
<td>16.05 (11.64 – 19.29)</td>
</tr>
</tbody>
</table>
REFERENCES:


